Recombinant Anti-human CD3e Monoclonal Antibody (Clone: UCHT1), Human IgG1 Fc Silent Kappa
Attributs du produit
The antibody binds to CD3 epsilon of the T cell receptor-CD3 complex found only on mature T cells and medullary thymocytes. An interaction between T cells, the antibody, and monocytes causes T-cell activation (mitogenesis) in vitro. On the other hand, the antibody blocks the unique association between the antigen receptor and CD3, and both the generation and function of cytotoxic T cells. After an initial dose of the antibody, T cells disappear from the circulation within minutes to hours. During treatment with the antibody, T cells bearing the usual array of surface molecules (CD2, CD4, and CD8) reappear in the peripheral blood circulation but these cells are devoid of CD3. After another 48 hours without the antibody, the normal array of surface molecules including CD3 appear again on all T cells. The selective removal of CD3 by internalization is thought to be the key mechanism of action of the antibody. Comodulation of the antigen receptor with CD3 explains the immunoblocking action of the antibody in vivo. The antibody is ineffective clinically if the CD3 target molecule is not modulated. The antibody is effective for induction of immunosuppression and for treating initial and steroid-resistant rejections.